Contact sales:+43 50 423


We use cookies on our website to provide you with the best possible experience. By clicking "Accept All" you agree to the use of all cookies and to our privacy policy.

Necessary cookies
Performance cookies (incl. US-provider)
On Demand Webinar

The e-signature in university practice: Efficient. Secure. European.

Discover the potential of digital signatures in university practice. Optimize administrative processes with maximum security. Together with our guest Daniel Nobis, Head of IT at the renowned Paracelsus Medical University (PMU), we will show you how you can significantly speed up your processes thanks to the introduction of an e-signature solution. The e-signature "sproof sign" is the European player for legally valid & GDPR-compliant signature processes and has been optimized for use cases in the university sector since its foundation in 2019.

Main topics:

  • The e-signature for administrative processes with students and in administration
  • Legal framework, national and international laws in the field of digital signatures
  • To what extent can a digitalized contract process reduce costs and save resources?
  • Live demonstration of the applications of sproof sign
  • Experience report of the PMU Salzburg after 4 years of e-signature

Find out more about the #1 in digital signing

Arrange a personal appointment (30 min)

We will evaluate your use case together. Learn all about the potential of a digital signature workflow in your company.

Book demo appointment

White papers & e-books: Find the right guideline for your industry.

A collection of e-books, white papers and other resources to help you get started with digital signatures.

Download e-book

Demo video: Request your product tour (4 min)

Want to get a first impression? Verena from the sales team knows how to present our all-in-one platform for digital signing in a nutshell.

Watch demo video
sproof sign is the highest-rated provider in the e-signature category on the independent evaluation platform OMR Reviews for Q3 and Q4 2023, as well as Q1 2024.